Expected earnings - NewAmsterdam Pharma Company N.V.
Source: US Earnings Reports
NewAmsterdam Pharma Company N.V. (NAMS) is expected to report $-0.4 for Q4 2025
NewAmsterdam Pharma Company N.V.
NASDAQ: NAMS
NAMS Trading
-0.43% G/L:
$30.055 Last:
363,309 Volume:
$30.81 Open:
NAMS Latest News
March 06, 2026 04:01:00 pm
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 18, 2026 07:00:00 am
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
February 04, 2026 08:00:00 am
NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit
NAMS Stock Data
$3,956,205,152
62,439,780
1.15%
35
N/A
Biotechnology & Life Sciences
Healthcare
NL
Naarden
